IC
CRDL

Ikarian Capital’s Cardiol Therapeutics CRDL Stock Holding History

Ikarian Capital’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.52M Buy
3,325,000
+600,000
+22% +$759K 0.38% 69
2026
Q1 		$3.68M Buy
+2,725,000
New +$2.8M 0.3% 74

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Ikarian Capital's CRDL Position: Q2 2026 in Review

Ikarian Capital increased its Cardiol Therapeutics (CRDL) stake by 22% in Q2 2026, buying an estimated $759K and bringing the position to 3,325,000 shares worth $3.52M. The position accounts for 0.38% of the portfolio, ranked #69.

Ikarian Capital first reported a position in CRDL in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.68M in Q1 2026. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Ikarian Capital held 3,325,000 shares of Cardiol Therapeutics worth $3.52M as of Q2 2026.
  • Ikarian Capital bought 600,000 Cardiol Therapeutics shares in Q2 2026, an estimated $759K.
  • Cardiol Therapeutics made up 0.38% of Ikarian Capital's portfolio in Q2 2026, its #69 holding.
  • Ikarian Capital first reported a position in Cardiol Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Ikarian Capital's Cardiol Therapeutics position peaked at $3.68M in Q1 2026.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.